Rev­o­lu­tion Med­i­ci­nes' RAS in­hibitor shows promise in ear­ly-stage pan­cre­at­ic can­cer tri­al

Rev­o­lu­tion Med­i­cines’ ex­per­i­men­tal drug staved off can­cer pro­gres­sion for sev­en and a half months in sec­ond-line metasta­t­ic pan­cre­at­ic can­cer pa­tients with a va­ri­ety of can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER